Evidence map›Paper›PMID 41222055›Full record

ArticleHuman vaccines & immunotherapeutics2025

Nationwide survey of municipal policies and COVID-19 vaccination uptake among older adults in Japan during 2024-2025.

Masaki Machida, Akira Nomachi, Kosuke Tanabe, Shuhei Ito, Tomoki Nakaya, Takashi Matono

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masaki MachidaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.
Akira NomachiVaccine Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan.
Kosuke TanabeVaccine Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan.
Shuhei ItoVaccine Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan.
Tomoki NakayaGraduate School of Environmental Studies, Tohoku University, Sendai, Japan.
Takashi MatonoDivision of Infectious Disease and Hospital Epidemiology, Saga University Hospital, Saga, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many countries continue to recommend COVID-19 vaccination, primarily to older adults. Following the transition of the national immunization program for COVID-19 vaccination in Japan in April 2024, implementation was delegated to municipalities. However, vaccination uptake and its associated factors, particularly municipal-level policies, remain unclear. This ecological study clarifies the factor associated with COVID-19 vaccination uptake among older adults aged ≥65 years in Japan during 2024-2025 by analyzing 1,740 municipalities. Municipal vaccination uptake among individuals aged ≥65 years was estimated from vaccine distribution data for the period. We examined the associations of uptake with municipal policies and sociodemographic factors using negative binomial regression, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated. The mean estimated vaccination uptake across Japan was 17.9%. Individual notification via mailed vaccine screening questionnaires had the largest effect, with higher uptake (IRR 1.57; 95% CI, 1.37-1.80). Low out-of-pocket expenses were also associated with higher uptake (IRR 1.31; 95% CI, 1.12-1.52 for ≤2,000 JPY, Reference: ≥3,001 JPY). A higher proportion of those aged ≥75 (IRR 1.03; 95% CI, 1.01-1.05) and a higher number of physicians (IRR 1.03; 95% CI, 1.00-1.06) were positively associated with uptake as well. Conversely, the area deprivation index was associated with lower uptake (IRR 0.87; 95% CI, 0.76-0.98). Proactive municipal strategies (individual notifications and subsidies to reduce out-of-pocket expenses) were significantly associated with increased vaccination uptake. To ensure equitable access and mitigate disparities, future vaccination campaigns should incorporate outreach measures to address socioeconomic barriers.

Indexed as

COVID-19COVID-19 VaccinesHealth PolicyImmunization ProgramsVaccinationVaccination CoverageAgedAged, 80 and overFemaleHumansJapanMaleSARS-CoV-2Surveys and QuestionnairesCOVID-19 VaccinesCOVID-19Japanmunicipalityout-of-pocket expensepolicyrespiratory infectionsocioeconomic statusvaccination strategyvaccine uptake

Identifiers

PMID41222055
PMCPMC12622345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.